| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.vistapharmaceuticals.com | |
| Market Cap | 24.91 Cr. | |
| Enterprise Value(EV) | 41.90 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.23 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 32.02 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 9.64 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 0.70 | Calculated using Price: 6.77 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 3.68 Cr. | 36,793,908 Shares |
| FaceValue | 2 | |
| Company Profile | ||
| Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America. | ||
| 1 Day |
|
+2.65% |
| 1 Week |
|
+3.41% |
| 1 Month |
|
+3.87% |
| 3 Month |
|
-1.41% |
| 6 Month |
|
-38.77% |
| 1 Year |
|
-24.62% |
| 2 Year |
|
-26.53% |
| 5 Year |
|
-75.42% |
| 10 Year |
|
+1.45% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 0.94 | 5.27 | 13.94 | 7.15 | 8.97 | 10.19 | 3.15 | -11.68 | -6.03 | |
| Return on Capital Employed (%) | 2.06 | 5.38 | 14.16 | 9.57 | 8.92 | 12.42 | 6.28 | -5.20 | -4.60 | |
| Return on Assets (%) | 0.55 | 3.27 | 7.39 | 3.15 | 3.70 | 4.67 | 1.78 | -7.11 | -3.65 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 9 | 9 | 10 | 11 | 17 | 32 | 36 | 30 | 33 | 35 | |
| Non Curr. Liab. | 0 | 0 | 0 | 8 | 5 | 6 | 6 | 5 | 11 | 13 | |
| Curr. Liab. | 6 | 5 | 12 | 7 | 19 | 15 | 11 | 16 | 9 | 4 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 14 | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 | |
| Non Curr. Assets | 13 | 12 | 11 | 10 | 16 | 25 | 29 | 30 | 37 | 37 | |
| Curr. Assets | 2 | 2 | 12 | 16 | 26 | 28 | 23 | 21 | 15 | 15 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 14 | 14 | 23 | 26 | 41 | 53 | 53 | 51 | 53 | 52 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 7 | 8 | 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | |
| Total Income | 7 | 8 | 14 | 15 | 24 | 29 | 34 | 27 | 2 | 1 | |
| Total Expenditure | -7 | -7 | -11 | -13 | -21 | -24 | -30 | -28 | -3 | -2 | |
| PBIDT | 1 | 1 | 3 | 3 | 3 | 6 | 4 | -1 | -1 | -1 | |
| Interest | 0 | 0 | -1 | -1 | -2 | -2 | -2 | -2 | -1 | ||
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 2 | 2 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | |
| Adjusted EPS | 0 | 0 | 1 | 0 | 0 | 1 | 0 | -1 | -1 | 0 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | -4 | -3 | 3 | -5 | 3 | 1 | -7 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | 0 | -4 | -11 | -6 | -2 | 0 | |
| Cash Fr. Finan. | 0 | 0 | 4 | 3 | 6 | 11 | 1 | 0 | 7 | ||
| Net Change | 0 | 0 | 0 | 0 | 5 | -4 | -1 | -1 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 6 | 2 | 1 | 0 | 0 |
|
Sat, 13 Aug 2022
Board Meeting Outcome for OUTCOME OF BOARD MEETING With reference to the subject cited it is hereby informed that the Board of Directors of the Company at its Meeting held on Saturday 13th August 2022 at 3:00 PM at the corporate office of the Company inter-alia considered and approved the following:1. Un-Audited Financial Results for the quarter ended 30th June 2022.2. Limited Review Report for the quarter ended 30th June 2022.3. Draft Board of Directors Report on the companys activities for the financial year ended March 31st 2022.4. To convene the Annual General Meeting of the company for the financial year 2021-22.5. Draft Notice for the Annual General Meeting of the Members of the Company.6. Appointment of Mr. NVSS Suryanarayana Rao Practicing Company Secretary as Scrutinizer for E-voting at the ensuing Annual General Meeting.Kindly take the same on record and acknowledge the receipt of the same. |
|
Sat, 13 Aug 2022
FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE 2022 With reference to the subject cited it is hereby informed that the Board of Directors of the Company at its meeting held on Saturday 13th August 2022 at 3.00 P.M. at the Corporate office of the Company interalia considered and approved the unaudited Financial Results for the quarter ended 30th June 2022.Copy of un-audited Financial Results for the quarter ended 30th June 2022 and Limited review Report is enclosed herewith.Kindly take the same on record and acknowledge the receipt of the same. |
|
Fri, 05 Aug 2022
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 13.08.2022 VISTA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve With reference to the subject cited the meeting of the Board of Directors of the Company M/s. Vista Pharmaceuticals Limited will be held on Friday 13.08.2022 at 03.00 P.M at the Corporate office of the Company Situated at 7-1-212/A/70 1st Floor Plot No. 85 Shivbagh Ameerpet Hyderabad- 500016 Telangana inter-alia to discuss the following:1. To consider approve and take on record the un-audited Financial Results of the company for the quarter ended 30th June 2022.2. To consider and take note of Limited Review Report for the quarter ended 30th June 2022.3. To consider and approve the Board of Directors report for the financial year 2021-22.4. To fix time date and mode of Annual General meeting.5. Any other items with permission of chairman. |
| Fri, 12 Aug 2022 |
Close Crossing Last Month Close from Above
|
Opening at High
|
Close Within 52 Week Low Zone
|
High Decrease 3 Months
|
High Decrease 6 Months
|
Equities
M.F.
Sectors